Connor, Clark & Lunn Investment Management (CC&L)
HBIO icon

Connor, Clark & Lunn Investment Management (CC&L)’s Harvard Bioscience HBIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,003
Closed -$422K – 1501
2024
Q4 		$422K Buy
20,003
+2,002
+11% +$46K ﹤0.01% 1186
2024
Q3 		$484K Buy
18,001
+2,961
+20% +$87.2K ﹤0.01% 1104
2024
Q2 		$429K Buy
15,040
+634
+4% +$22.2K ﹤0.01% 1089
2024
Q1 		$611K Buy
14,406
+257
+2% +$11.6K ﹤0.01% 1049
2023
Q4 		$757K Sell
14,149
-2,033
-13% -$91.8K ﹤0.01% 940
2023
Q3 		$696K Buy
16,182
+6,317
+64% +$291K ﹤0.01% 937
2023
Q2 		$542K Buy
+9,865
New +$541K ﹤0.01% 969
2022
Q1 		– Sell
-5,425
Closed -$382K – 1112
2021
Q4 		$382K Sell
5,425
-1,506
-22% -$107K ﹤0.01% 855
2021
Q3 		$484K Buy
6,931
+775
+13% +$61.7K ﹤0.01% 777
2021
Q2 		$513K Sell
6,156
-114
-2% -$8.06K ﹤0.01% 783
2021
Q1 		$342K Sell
6,270
-1,735
-22% -$84.4K ﹤0.01% 843
2020
Q4 		$343K Sell
8,005
-1,817
-18% -$67.8K ﹤0.01% 767
2020
Q3 		$296K Buy
9,822
+4,942
+101% +$166K ﹤0.01% 791
2020
Q2 		$151K Buy
4,880
+302
+7% +$8.14K ﹤0.01% 924
2020
Q1 		$101K Buy
4,578
+458
+11% +$12.4K ﹤0.01% 931
2019
Q4 		$126K Sell
4,120
-50
-1% -$1.44K ﹤0.01% 867
2019
Q3 		$128K Buy
+4,170
New +$104K ﹤0.01% 892
2015
Q1 		– Sell
-1,280
Closed -$73K – 589
2014
Q4 		$73K Buy
1,280
+70
+6% +$3.34K ﹤0.01% 556
2014
Q3 		$49K Buy
+1,210
New +$55.6K ﹤0.01% 535

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s HBIO Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Harvard Bioscience (HBIO) in Q1 2025, closing a stake of 20,003 shares — an estimated $422K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in HBIO in Q3 2014 and held it in 19 quarters. The position peaked at $757K in Q4 2023. 92 funds tracked by Wall St. Rank hold HBIO as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Harvard Bioscience position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 20,003 Harvard Bioscience shares in Q1 2025, an estimated $422K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Harvard Bioscience in Q3 2014 and held it in 19 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Harvard Bioscience position peaked at $757K in Q4 2023.
  • 92 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.